NCT07200479View on ClinicalTrials.gov

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

June 28, 2027

Study Completion Date

December 30, 2027

Conditions
Relapsed/Refractory B-Cell Neoplasms
Interventions
DRUG

CAR T cells chimeric antigen receptor cells

CT1194D cells infusion

Trial Locations (3)

301617

China Institute of Hematology and Blood Diseases Hospital, Tianjin

China Institute of Hematology and Blood Diseases Hospital, Tianjin

China Institute of Hematology and Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER